文献速递临床试验与 GCP基础与转化研究

改善终末期肾病炎症负担的新范式(rePAIR):随机对照试验研究方案

Novel PAradigm to improve Inflammatory burden in end stage Renal disease (rePAIR): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2018-07-11

rePAIR 研究是一项 pilot 和可行性、平行组、随机对照临床试验,计划招募 72 例合并牙周炎的 ESRD 成人患者,比较标准治疗与重复非手术牙周治疗对全身及口腔炎症负担的影响。主要结局为血清 CRP 从基线至 6 个月的变化,次要结局包括 IL-6、F2 异前列腺素和 F2 异前列烷及患者报告和临床口腔结局。

要点

  • 针对 ESRD 合并牙周炎患者,采用持续维护和口腔健康行为改变控制牙周炎症。
  • 主要结局为 6 个月内血清 CRP 变化,次要结局包括 IL-6 和氧化应激标志物。
  • 试验遵循 CONSORT 指南,强调随机分配隐藏、结局评估盲法和性别多样性分析。

核心结论

  • 持续牙周维护和口腔健康行为改变可能改善 ESRD 患者全身炎症、氧化应激、口腔健康和生活质量,但尚待试验验证。

研究设计与样本

  • pilot 和可行性、平行组、随机对照临床试验,计划招募 72 例合并牙周炎的 ESRD 成人患者,采用计算机区组随机化。

关键数值与推荐

  • 纳入年龄大于 21 岁、至少 12 颗牙、过去一年无牙周治疗史的 ESRD 合并牙周炎成人患者。
  • 主要结局为血清 CRP 从基线至 6 个月的变化,次要结局包括 IL-6、F2 异前列腺素和 F2 异前列烷。
  • 试验注册于 ClinicalTrials.gov,编号 NCT03241511,注册日期 2017 年 8 月 7 日。

临床怎么用

  • 为 ESRD 患者牙周炎症管理提供随机对照试验证据,强调持续维护而非单次干预。

局限性

  • 为 pilot 和可行性试验,样本量 72 例,主要目的是可行性评估而非确证疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Given the importance of inflammation as a predictor of poor outcomes in End Stage Renal Disease (ESRD), reductions in inflammatory biomarkers have been proposed as a critical target in this population. This study targets chronic periodontitis, an oral inflammatory disease of microbial etiology causing persistent inflammation in ESRD. Unlike the previously reported episodic periodontal interventions, we propose to control periodontal inflammation with a continuous maintenance and oral health behavior modifications. We hypothesize that this strategy will improve systemic inflammation and oxidative stress, oral health and quality of life within the 6-month observation period. METHODS: The rePAIR (novel PAradigm to improve Inflammatory burden in ESRD) study is a pilot and feasibility, parallel-arm, and randomized controlled clinical trial that will recruit 72 ESRD subjects with periodontitis in a model of computerized block randomization. This trial aims to compare the effect of standard-of-care vs. repeated non-surgical periodontal therapy on systemic and oral inflammatory burden. This trial will recruit ESRD adult patients with periodontitis older than 21 years old with a minimum of 12 teeth and no history of periodontal treatment within a year. The trial will examine serum C-reactive protein (CRP) (primary outcome) as a biomarker of inflammation as well as interleukin-6 (IL-6), F2 isofurans and F2 isoprostanes (secondary outcomes) and compare their difference between groups from baseline to 6 months. The trial will also compare the difference between groups in patient-centered and clinical oral outcomes from baseline to 6 months. DISCUSSION: The trial follows a rigorous and transparent study design capturing elements such as pre-specified eligibility criteria, pre-specified primary and secondary outcomes, detailed intervention description to allow replication, intervention random allocation and concealment, blinding in outcome assessment, appropriate sample size calculations, explanation of interim analysis, as per CONSORT Guidelines. Further, gender diversity is secured not only at recruitment but also throughout the trial and during the analysis. Therefore, treatment response outcomes will be examined per gender category. In order to manage anticipated problems, the protocol has included alternative approaches. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03241511 . Registered on 7 August 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Trivedi R, Fares G, Nunez VB, et al. Novel PAradigm to improve Inflammatory burden in end stage Renal disease (rePAIR): study protocol for a randomized controlled trial. Trials. 2018. PMID: 29996883. doi:10.1186/s13063-018-2760-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。